Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
Continued high demand for vaccine manufacturing technologies saw life sciences emerge as one of the few positives for industrial processing specialist Pall in Q1.
Revenues from Pall’s biopharmaceuticals division grew in fiscal 2009, excluding foreign currency changes, with the company benefiting from the “thriving market” for vaccines and expanding adoption of single-use systems.
Pall CEO Eric Krasnoff says delayed drug industry capital expenditure and moves to conserve inventory in the current global gloom caused life science sales to fall 8 per cent for the second quarter.
Pall Life Sciences has launched its Allegro 3D biocontainers, which have been designed to improve the performance of the company’s large-scale, single use manufacturing systems.
As single-use technologies become more and more popular for use in
biopharmaceutical manufacturing, Pall is following market demands
bolstering its product line by adding a number of disposable
products to its portfolio.
The ongoing intellectual property tussle between Pall and Entegris
continues with Pall claiming Entegris' Impact filter cartridge line
infringes four Pall patents.
Filtration system Pall Corporation reported its first quarter
earnings which revealed earnings rose by 16 per cent, propelled by
growth in its industrial and biopharmaceuticals segments.
Filtration and separation company Pall has made another acquisition
in the chromatography sector with the purchase of Euroflow (UK) for
an undisclosed amount.
Pall has been granted European Union and US approval for a
purification process used in biopharmaceutical production that can
reduce the batch testing requirements of manufacturers, as well as
reducing the risk of virus contamination.
Filtration and purification specialist Pall has reported a 12.5 per
cent hike in first-quarter sales to $374 million (€310m), with life
sciences putting in a strong showing, up 15.5 per cent to $152
million.
Pall has reported a 10 per cent rise in sales to $471 million
(€430m) in the fourth quarter, boosted by currencies and the
recently-acquired FSG operations.